About S-adenosylmethionine-dependent nucleotide dehydratase RSAD2
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2) is a protein
from Homo sapiens identified by UniProt accession
Q8WXG1, 361 residues long.
MolForge cross-references it against 0 known binders and
241 disease associations.
Target properties
| Protein name | S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 |
| UniProt accession | Q8WXG1 |
| Gene | RSAD2 |
| Organism | Homo sapiens |
| Length | 361 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (241)
Diseases linked to this target (Open Targets).
- balding measurement · score 0.26
- hair shape measurement · score 0.25
- risk-taking behaviour · score 0.25
- visual perception measurement · score 0.23
- neurofibrillary tangles measurement · score 0.23
- alopecia · score 0.20
- androgenetic alopecia · score 0.19
- disease progression measurement · score 0.18
- metastasis measurement · score 0.18
- breast milk measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WXG1-F1 | alphafold | PREDICTED | 87.36 | — |
Amino-acid sequence (361 residues)
MWVLTPAAFA GKLLSVFRQP LSSLWRSLVP LFCWLRATFW LLATKRRKQQ LVLRGPDETK EEEEDPPLPT TPTSVNYHFT RQCNYKCGFC FHTAKTSFVL PLEEAKRGLL LLKEAGMEKI NFSGGEPFLQ DRGEYLGKLV RFCKVELRLP SVSIVSNGSL IRERWFQNYG EYLDILAISC DSFDEEVNVL IGRGQGKKNH VENLQKLRRW CRDYRVAFKI NSVINRFNVE EDMTEQIKAL NPVRWKVFQC LLIEGENCGE DALREAERFV IGDEEFERFL ERHKEVSCLV PESNQKMKDS YLILDEYMRF LNCRKGRKDP SKSILDVGVE EAIKFSGFDE KMFLKRGGKY IWSKADLKLD W
Explore S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets